<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Riluzole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Riluzole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Riluzole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12109" href="/d/html/12109.html" rel="external">see "Riluzole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218370"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Exservan;</li>
<li>Rilutek;</li>
<li>Tiglutik [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868154"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Riluzole;</li>
<li>MYLAN-Riluzole;</li>
<li>Rilutek</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F218406"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Glutamate Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F218375"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a1f0b9b-307c-4dfa-ad3e-6402def7e3f4">Amyotrophic lateral sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyotrophic lateral sclerosis:</b>
<b>Oral:</b> 50 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992048"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989341"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Avoid use in patients with baseline hepatic transaminases &gt;5 times ULN; discontinue use if evidence of hepatic impairment occurs during treatment.</p></div>
<div class="block dot drugH1Div" id="F51895017"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary toxicity: If interstitial lung disease develops, discontinue riluzole immediately.</p></div>
<div class="block doe drugH1Div" id="F218376"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F218340"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (16%), oral hypoesthesia (oral film: 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&gt;ULN: 50%; &gt;3 x ULN: 8%; &gt;5 x ULN: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system<b>: </b>Dizziness (females 11%; males: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5%), peripheral edema (3%), tachycardia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema (2%), pruritus (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%), flatulence (3%), oral paresthesia (2%), vomiting (4%), xerostomia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system<b>: </b>Drowsiness (2%), insomnia (4%), vertigo (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Decreased lung function (10%), increased cough (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Severe neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease (including hypersensitivity pneumonitis)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (acute), toxic hepatitis (icteric)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal tubular disease</p></div>
<div class="block coi drugH1Div" id="F218354"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to riluzole or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hepatic disease or baseline serum transaminases &gt;3 times ULN; pregnancy; breast-feeding</p></div>
<div class="block war drugH1Div" id="F218337"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause dizziness or somnolence, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: May cause drug-induced hepatic injury (including fatality); asymptomatic elevations of hepatic transaminases may also occur. Elevations of transaminases may occur within 3 months of use. Use is not recommended in patients who develop hepatic transaminases &gt;5 times the upper limit of normal. Monitor for hepatic injury; discontinue use if evidence of hepatic dysfunction occurs (eg, elevated bilirubin).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neutropenia: Severe neutropenia has been reported (ANC &lt;500/mm<sup>3</sup>) within the first 2 months of therapy. Evaluate patients with febrile illnesses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary disorders: Interstitial lung disease (ILD), including hypersensitivity pneumonitis, has occurred. Discontinue therapy immediately if ILD occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p></div>
<div class="block foc drugH1Div" id="F218348"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exservan: 50 mg (60 ea) [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiglutik: 50 mg/10 mL (300 mL [DSC]) [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rilutek: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block geq drugH1Div" id="F218333"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F218356"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Film</b> (Exservan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $62.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Rilutek Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $61.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Riluzole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $19.14 - $37.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868155"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rilutek: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block adm drugH1Div" id="F218351"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Film: Administer at least 1 hour before or 2 hours after a meal; only one film should be taken at a time. Place film on tongue and allow to dissolve; do not administer with liquids. As film dissolves, swallow saliva in a normal manner but avoid chewing, spitting, or talking. Do not cut or split film.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension, tablet: Administer orally or through a percutaneous endoscopic gastrostomy (PEG) tube (silicone or polyurethane) at least 1 hour before or 2 hours after a meal. Gently shake suspension for ≥30 seconds prior to administration. If administered via PEG tube, flush tube with 30 mL of water before and after administration.</p></div>
<div class="block use drugH1Div" id="F218350"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Amyotrophic lateral sclerosis: </b>Treatment of patients with amyotrophic lateral sclerosis (ALS); may extend survival and/or time to tracheostomy</p></div>
<div class="block cyt drugH1Div" id="F218401"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F218342"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May enhance the adverse/toxic effect of Riluzole. Specifically, the risk of hepatotoxicity may be increased. Management: Consider alternatives to allopurinol in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Riluzole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Riluzole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: May enhance the adverse/toxic effect of Riluzole. Specifically, the risk of hepatotoxicity may be increased. Management: Consider alternatives to methyldopa  in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfaSALAzine: May enhance the adverse/toxic effect of Riluzole. Specifically, the risk of hepatotoxicity may be increased. Management: Consider alternatives to sulfasalazine in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Riluzole.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F218367"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">A high-fat meal decreases absorption of riluzole (decreasing AUC by 20% and peak blood levels by 45%). Management: Administer at the same time each day, at least 1 hour before or 2 hours after a meal.</p></div>
<div class="block pri drugH1Div" id="F218357"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20548382"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if riluzole is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F218346"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum aminotransferases including ALT (baseline and periodically during therapy); signs and symptoms of hepatic injury (every month for the first 3 months and periodically thereafter).</p></div>
<div class="block pha drugH1Div" id="F218336"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mechanism of action is not known. Pharmacologic properties include inhibitory effect on glutamate release, inactivation of voltage-dependent sodium channels; and ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors</p></div>
<div class="block phk drugH1Div" id="F218353"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: High-fat meal decreases AUC by 9% and peak blood levels by 55%.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: High-fat meal decreases AUC by 20% and peak blood levels by 45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 96%, primarily to albumin and lipoproteins</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Suspension: 0.8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~3.4 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP1A2 and UGT-HP4</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Absolute: ~60%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (90%; 2% as unchanged drug) and feces (5%)</p></div>
<div class="block phksp drugH1Div" id="F51220967"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC increased by about 1.7- and 3-fold in patients with mild and moderate chronic hepatic insufficiency, respectively. The pharmacokinetics have not been studied in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Mean AUC was found to be 45% higher in women compared with men.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Clearance was 50% lower in male Japanese patients than in white patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Smoking: Clearance was 20% greater in smokers compared to nonsmokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218359"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Edilosiv | Rilutek | Teglutik</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol Easypharm | Riluzol pmcs | Riluzol stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo riluzole | Pharmacor riluzole | Rilutek | Riluzole sandoz | Riluzole winthrop | Teglutik</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol actavis | Teglutik</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol | Tekzor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rizuril | Teglutik</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Extensik | Rilutek | Riluzol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol pmcs | Sclefic</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Glentek | Rilutek | Riluzol 1 A Pharma | Riluzol actavis | Riluzol AL | Riluzol alkem | Riluzol Beta | Riluzol CT | Riluzol Heumann | Riluzol Hexal | Riluzol Hormosan | Riluzol mylan | Riluzol Neuraxpharm | Riluzol Ratiopharm | Riluzol stada | Riluzol sun | Riluzol Zentiva | Teglutik</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol actavis | Riluzol combino pharm | Riluzol genfarma | Riluzol mylan | Riluzol normon | Riluzol pmcs | Riluzol sun | Riluzol Teva | Teglutik</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Teglutik</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzole Actavis | Riluzole Biogaran | Riluzole EG | Riluzole mylan | Riluzole pmcs | Riluzole sandoz | Riluzole Teva | Riluzole Zentiva | Teglutik</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzole Teva | Teglutik</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Teglutik</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo riluzole | Rilutek</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Alsemol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fanizan | Rilutek | Sclefic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Teglutik</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzolo | Riluzolo Actavis | Riluzolo Sandoz | Riluzolo Sun | Riluzolo teva | Teglutik</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Yooritek</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzole Zentiva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Riluzol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glentek | Rilutek | Riluzol | Riluzol actavis | Riluzol cf | Riluzol mylan | Riluzol pch | Riluzol sandoz | Riluzol sun</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol | Teglutik</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol pmcs | Sclefic | Zolerilis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Exservan | Rilutek | Tiglutik</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol | Riluzol actavis | Riluzol combino | Riluzol Generis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Glentek | Rilutek | Riluzol abacus medicine | Riluzol actavis | Riluzol pmcs | Riluzol stada | Riluzole 2care4 | Riluzole Teva | Teglutik</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Sclefic | Teglutik</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol pmcs</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Rilutek | Riluzol pmcs | Riluzole mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Laidec | Rilutek | Ritek</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Borizolum | Rilutek</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rilutek</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Exservan (riluzole) oral film [prescribing information]. Warren, NJ: Aquestive Therapeutics; July 2022.</div>
</li>
<li>
<div class="reference">
                  Rilutek (riluzole) [prescribing information]. Zug, Switzerland: Covis Pharmaceuticals, Inc; July 2016.</div>
</li>
<li>
<div class="reference">
                  Rilutek (riluzole) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis; May 2010.</div>
</li>
<li>
<div class="reference">
                  Tiglutik (riluzole) [prescribing information]. Berwyn, PA: ITF Pharma Inc; December 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9865 Version 220.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
